Sarit Polsky1, Halis K Akturk1. 1. Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Abstract
BACKGROUND: Hybrid closed-loop (HCL) therapy is rarely studied in pregnancy. We present three cases of women with type 1 diabetes who used the Medtronic 670G HCL system for most or all of gestation. METHODS: The Medtronic 670G system has a manual mode (no automated insulin delivery) and an auto mode (AM, HCL therapy). Women in this case series used AM off-label in gestation. RESULTS: Case 1 started HCL therapy in the second trimester, her sensor glucose time spent <3.9 and >10 mmol/L improved thereafter. Case 1 had average sensor glucose (ASG) levels of 6.4 ± 2.4 mmol/L in the first trimester, 7.0 ± 2.7 mmol/L in the second trimester before HCL use, 7.1 ± 2.1 mmol/L in the second trimester after HCL use, and 6.8 ± 1.9 mmol/L in the third trimester. Case 1 continued AM during operative delivery and post-partum. Cases 2 and 3 used HCL therapy throughout gestation but with inconsistent time in AM. When they increased time in AM their glycaemic indices improved. Case 2 had ASG of 9.5 ± 3.4, 8.6 ± 2.9, and 7.9 ± 2.5 mmol/L in the first through third trimesters, respectively. Case 3 had ASG of 11.1 ± 4.8 and 3.9 to 10 mmol/L in the first and second trimesters, respectively. Case 2 continued HCL therapy post-partum, Case 3 did not. CONCLUSIONS: CareLink® Clinical Software only reports the non-pregnant time in range. Nonetheless, this represents the first report of HCL therapy in pregnancy with a system approved by the Food and Drug Administration in non-pregnant populations.
BACKGROUND: Hybrid closed-loop (HCL) therapy is rarely studied in pregnancy. We present three cases of women with type 1 diabetes who used the Medtronic 670G HCL system for most or all of gestation. METHODS: The Medtronic 670G system has a manual mode (no automated insulin delivery) and an auto mode (AM, HCL therapy). Women in this case series used AM off-label in gestation. RESULTS: Case 1 started HCL therapy in the second trimester, her sensor glucose time spent <3.9 and >10 mmol/L improved thereafter. Case 1 had average sensor glucose (ASG) levels of 6.4 ± 2.4 mmol/L in the first trimester, 7.0 ± 2.7 mmol/L in the second trimester before HCL use, 7.1 ± 2.1 mmol/L in the second trimester after HCL use, and 6.8 ± 1.9 mmol/L in the third trimester. Case 1 continued AM during operative delivery and post-partum. Cases 2 and 3 used HCL therapy throughout gestation but with inconsistent time in AM. When they increased time in AM their glycaemic indices improved. Case 2 had ASG of 9.5 ± 3.4, 8.6 ± 2.9, and 7.9 ± 2.5 mmol/L in the first through third trimesters, respectively. Case 3 had ASG of 11.1 ± 4.8 and 3.9 to 10 mmol/L in the first and second trimesters, respectively. Case 2 continued HCL therapy post-partum, Case 3 did not. CONCLUSIONS: CareLink® Clinical Software only reports the non-pregnant time in range. Nonetheless, this represents the first report of HCL therapy in pregnancy with a system approved by the Food and Drug Administration in non-pregnant populations.
Authors: Basak Ozaslan; Carol J Levy; Yogish C Kudva; Jordan E Pinsker; Grenye O'Malley; Ravinder Jeet Kaur; Kristin Castorino; Camilla Levister; Mari Charisse Trinidad; Donna Desjardins; Mei Mei Church; Mitchell Plesser; Shelly McCrady-Spitzer; Selassie Ogyaadu; Kristen Nelson; Corey Reid; Sunil Deshpande; Walter K Kremers; Francis J Doyle; Barak Rosenn; Eyal Dassau Journal: Diabetes Technol Ther Date: 2022-04-26 Impact factor: 7.337
Authors: Guillermo E Guzmán Gómez; Julian A Viggiano; A Silva-De Las Salas; Veline Martínez; María A Urbano Bonilla Journal: Case Rep Endocrinol Date: 2021-09-21
Authors: Tara T M Lee; Corinne Collett; Mei-See Man; Matt Hammond; Lee Shepstone; Sara Hartnell; Eleanor Gurnell; Caroline Byrne; Eleanor M Scott; Robert S Lindsay; Damian Morris; Anna Brackenridge; Anna R Dover; Rebecca M Reynolds; Katharine F Hunt; David R McCance; Katharine Barnard-Kelly; David Rankin; Julia Lawton; Laura E Bocchino; Judy Sibayan; Craig Kollman; Malgorzata E Wilinska; Roman Hovorka; Helen R Murphy Journal: BMC Pregnancy Childbirth Date: 2022-04-05 Impact factor: 3.007